SCHEMBL2864790

SCHEMBL2864790

COc1c(Br)ccc2[nH]nc(-c3ccc4ccccc4c3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.49
CDK4 P11802 2/20 0.49
CCNA2 P20248 2/20 0.49
CCND1 P24385 2/20 0.49
CCND3 P30281 2/20 0.49
KDR P35968 2/20 0.49
PDGFRB P09619 1/20 0.42
TTK P33981 2/20 0.40
MAPKAPK2 P49137 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2871126 0.86 KDR (0.50) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2861482 0.81 CDK4 (0.48) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL13636075 0.80 CDK4 (0.47) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL13635731 0.80 CDK4 (0.50) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2863072 0.80 TTK (0.47) TTKTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2864750 0.78 CDK2 (0.43) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2865609 0.78 CDK4 (0.46) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL6545434 0.78 CDK4 (0.45) CDK2CDK4CCNA2CCND1CCND3
SCHEMBL2858841 0.77 TUBB4A (0.42) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL2861862 0.77 TUBB4A (0.42) MAPKAPK2TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed
EP-1380576-A1 NOVEL 1H-INDAZOLE COMPOUND Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CDK2 50/4885CDK4 103/4885CCNA2 398/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 CDK2 154/4885CDK4 165/4885CCNA2 1567/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CDK2 50/4885CDK4 103/4885CCNA2 398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.